LETTERS TO THE EDITOR Normal G-CSF-mobilized CD34
+ peripheral blood stem cells in paroxysmal nocturnal hemoglobinuria: a perspective for autologous transplantation
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired
Very low levels of CD34 + PBSC (less than 0.04%) were detected before G-CSF treatment (Table 1) . However, after 5 genetic disorder resulting from the expansion of a clone (or clones) that arises by a somatic mutation occurring in the Xdays of G-CSF, the three patients mobilized a number of CD34 PBSC, enough for a cytofluorimetric analysis. The prolinked PIG-A gene and involving a pluripotent hematopoietic stem cell. [1] [2] [3] [4] Cells of abnormal clones are deficient in all those portional and absolute levels of CD34 + PBSC ranged from 0.05 to 0.4%, and from 7.5 to 41.2/l, respectively (Table 1) . plasma membrane proteins that, in normal subjects, are anchored by a glycosyl-phosphatidyl-inositol (GPI) molecule,
In contrast to non-PNH patients, most of these mobilized CD34 + PBSC did not express the CD59 antigen, thus suggestwhose biochemical synthesis, initially regulated by the PIG-A gene, is altered in PNH patients. 4, 5 The demonstration of the ing that the majority of them belonged to the mutated PNH clone (Figure 1 ). However, a variable proportion (13.4-absence of such GPI-linked proteins on circulating blood cells is now widely used as a diagnostic test for PNH, which pro-40.3%) showed an apparently normal phenotype, co-expressing both CD34 and the GPI-linked antigen CD59 ( Figure 1 ). vides a specific marker for distinguishing affected from normal cells. 6, 7 Peripheral blood stem cells (PBSC), usually identified No significant adverse effects due to G-CSF were recorded during and immediately after the study. by their positivity for CD34 antigen and obtained in large amounts by mobilizing chemotherapy and/or growth factor Thus, we demonstrated the presence of CD34 + PBSC in PNH patients stimulated with G-CSF. More interestingly, a sigadministration, are extensively used as a source of autologous hematopoietic precursors for transplantation in several hemanificant proportion of these cells were, at least cytometrically, not involved in the mutated clone since they normally tologic disorders. The aim of the present study was to verify the presence of circulating normal hematopoietic precursors expressed the GPI-linked molecule CD59. Recently, similar findings have been observed in leukaphereses from unstimuin PNH, as a possible first step in the therapeutic perspective of autologous PBSC transplantation for these patients.
lated PNH subjects. 9 The present analysis is the first study to report a phenotypic evaluation of CD34 + PBSC achieved in We analyzed, by means of a double labeling cytofluorimetric assay, the presence of the GPI-linked molecule CD59
PNH patients receiving G-CSF in vivo. PNH patients released variable yields of normal PBSC. It remains to be defined (a membrane inhibitor of reactive lysis or MIRL) on CD34 + PBSC from three PNH patients (one male and two females, whether this reflects different proportions of non-clonal residual hematopoiesis, a fact that could have prognostic sig-20-44 years old), mobilized by in vivo administration of G-CSF (Neupogen, Dompé-Biotec, or Granulokine, Roche, nificance for the heterogeneous population of PNH patients. 10 In the clinical setting, the combination of leukapheresis 9 Milan, Italy; 300 g/day s.c. for 5 days). CD59 was selected from among various other GPI-linked molecules, since it was and administration of G-CSF could be a feasible approach to achieving a larger number of CD34 + PBSC in PNH patients. constantly expressed on 99-100% of CD34 + PBSC detected in 10 leukaphereses we performed after mobilizing chemo-
The adjunct of selective ex vivo expansion 11 of 'pure' CD34 + /CD59 + PBSC, could significantly increase the number therapy plus G-CSF in patients with neoplastic hematological disorders, which served as controls. All patients gave written of normal hematopoietic precursors potentially available, in the so far unexplored therapeutic perspective of an autologous informed consent for the entire procedure. Two of them have been previously reported among the first Italian examples of PBSC transplant in these patients. In the light of the so-called 'selective pressure hypothesis', according to which GPI-PIG-A gene mutations in PNH. 8 In brief, 100 l of whole mobilized peripheral blood were deficient cells are allowed to grow while normal cells are inhibited by immunological mechanisms, 3, 12 autologous simultaneously incubated at 4°C in the dark for 25 min with 10 l phycoerythrin or fluorescein-isothiocyanate-labeled transplantation of PBSC could permit a 'maximal' immunosuppression. A possible effect on the harmless PNH clone, monoclonal antibodies recognizing, respectively, CD34 (HPCA2, Becton Dickinson, San José, CA, USA) and CD59 however, should also be considered. Molecular studies are in progress in order to confirm the absence of PIG-A gene (CBL467, Cymbus Bio-Science, Alma Research, Firenze, Italy). After red blood cell lysing and washing twice by centrifugmutations in PNH CD34 + /CD59 + cells. ation in phosphate-buffered saline, the data were acquired on a FACSort flow cytometer (Becton Dickinson) equipped with a 15-mW argon laser emitting at 488 nm and Lysis II software. All channels were set for acquisition in the logarithmic mode. An initial acquisition gate was set according to side light scat- In the September 1996 issue of Leukemia, we commented on and incidentally, mice do not have an expressed homologue of the HLA-DP locus. a paper by Taylor et al previously published in the journal. 1, 2 Our main concern was the lack of statistical evaluation. In a Also in childhood ALL, we did not find a significant increase in the genotype frequencies in the whole group of following issue, a reply by two of the authors was published, 3 in which instead of replying to the main criticism on the lack 63 patients (17.5 vs 13.6%). 6 However, the homozygosity rates were different between boys and girls (27.7 vs 3.7%, of any significant increase in their report, Gokhale and Taylor chose to attempt to invalidate our unpublished results in P = 0.01) yielding a relative risk of 3.29 (95%, CI = 1.37-7.90) for boys homozygous for DR53 to develop common ALL (33.3 Hodgkin's disease as well as our previous findings in other hemopoietic malignancies.
vs 13.6%, P = 0.008). These findings have now been confirmed in an updated group of 84 patients. 11 Based on the Dorak et al are still persuaded that homozygosity for HLA-DR53 is the most consistent association in hemopoietic maligmolecular mimicry between HLA-DR53 antigen and viral proteins, 12 and this gender effect, we have been able to propose nancies as it has been shown in three leukemias (CML, ALL, CLL) in three different populations by molecular analysis. [4] [5] [6] a model which might be relevant in the development (not etiology) of childhood ALL.
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Also in AML, an HLA-DR53 association was noted in a study that used a specific monoclonal antibody. 7 In CLL, an HLAHomozygosity for HLA-DR53 precisely means homozygosity for the HLA-DRB4‫10ء‬ allele therefore mapping the suscep-DR53 association was previously reported in another British study. 8 In the first molecular HLA association study on leuketibility around the DRB4 locus. We did check the relevance of the HLA-DRB1 locus by scientific methods both in CML mia, we typed 112 patients and 432 local controls at 10 MHC loci to have a holistic view of the HLA complex and to avoid and CLL and did not find a stronger association with it. There is no reason to discuss the meaning of heterozygosity for spurious associations due to linkage disequilibrium. 4 By conventional analysis, there was no difference in the homozygos-DRB1 alleles as it is not the susceptibility locus. As discussed above there is enough reason to believe HLA-DR53 is the susity rates between patients and local controls (11.6 vs 13.4%, respectively). Most researchers in this field would have conceptibility allele in hemopoietic malignancies and this association may be HVR sequence-related. The seven consecutive cluded a lack of association. However, the oldest patient homozygous for HLA-DR53 was 52 years old (P = 0.004), and amino acids (LLERRRA) of the HVR3-encoded immunodominant epitope of HLA-DR53 is mimicked by pathogenic viruses the homozygosity rates in patients below and above the median age were different (25.7 vs 5.2%, P = 0.003). The including EBV which plays a role in the pathogenesis of Hodgkin's disease. 12 For this reason and also to investigate the role study on CLL further confirmed the influence of the DR53 homozygosity (corresponding figures being 18.6 vs 2.9%, of HLA-DR53 in another hemopoietic malignancy, we initiated a study on Hodgkin's disease. As clearly stated in our P = 0.03), and also showed the protective (delaying) effect of homozygosity for HLA-DR52. 6 The mean ages of patients with original communication, we only have 'preliminary data' that appeared as an 'abstract'. We have reported that in the class II CLL homozygous for DR53 and DR52 are 54.8 ± s.e. 3.7 vs 65.8 ± s.e. 2.8 years (P = 0.02; two-tailed t-test), respectively. region, there was no significant association even with the early-onset group. A detailed analysis of the patients homoThe corresponding figures in the CML group are 32.1 ± s.e. 3.1 vs 49.4 ± s.e. 5.0 years (P = 0.007). The overall age distrizygous for HLA-DR53 showed that seven of the eight patients with this genotype were under the median age (P = 0.06) and butions of these two groups of patients are also significantly different by the log-rank test both in CLL (P = 0.04) and CML the oldest patient homozygous for DR53 was 46 years old (P = 0.04). We now have more samples and are still collecting (P = 0.01). These significant observations are strikingly similar to those made by Lilly et al 9 in their original study on mice. consecutive patients' samples. The results will be presented when the study is complete. In a congenic mouse model, they showed the influence of the two homozygous genotypes (namely H-2 k and H-2 b ) on the We will not be surprised if Hodgkin's disease has the same association with HLA as other major hemopoietic maligrate of development of both virus-induced and spontaneous leukemia. Unlike homozygosity, heterozygosity for H-2 k did nancies despite their very different etiologies. Because HLA has no primary role in the etiology of these diseases, a certain not accelerate the development of leukemia. It has to be noted that H-2 k and HLA-DR53 are serologically cross-reactive, 10 HLA genotype may be 'associated' with more than one disease. This is not speculation but a simple fact repeatedly shown in different studies. This is no different from the well-
